Vitrolife names Elin Frostehav as its new CEO
Vitrolife has appointed Elin Frostehav as President and CEO effective May 1, 2027, or earlier. Rickard Ericsson will serve as interim CEO from November 1, 2026.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Swedish medical technology company Vitrolife Group said Elin Frostehav will become its President and Chief Executive Officer. She will take over as soon as practicable, and no later than May 1, 2027. Current CEO Bronwyn Brophy O'Connor will step down on November 1, 2026, according to Reuters and TradingView.
From November 1, 2026, Rickard Ericsson, Senior Vice President Innovation, will act as interim CEO. Frostehav currently leads Acute Care Therapies at Getinge and has previously worked at Semcon and FlexLink. Board Chair Jon Sigurdsson thanked Brophy O'Connor for her leadership and said he is confident in the new CEO's experience.
why it matters
A leadership change at a company with about 1,100 employees and headquarters in Gothenburg rarely moves the broader market. Investors following Vitrolife on Nasdaq Stockholm will watch how the new CEO plans to drive profitable growth after the transition period.
tags
instruments
sources
- Elin Frostehav Appointed CEO Of Vitrolife Group — Reuters, 26 October 2026 at 09:13 UTC
- Elin Frostehav appointed CEO of Vitrolife Group — TradingView, 26 October 2026 at 09:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗